Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naoxuekang is a Chinese patent medicine (CPM) formulated as capsules or dripping pills, primarily used in the convalescent period after stroke. It is indicated for symptoms such as hemiplegia, dysphasia, facial paralysis, blood stasis syndrome, and related manifestations like stiff tongue and sluggish speech. The mechanism of action is based on traditional Chinese medicine principles—invigorating Qi and promoting blood circulation to resolve blood stasis. Clinical studies have evaluated its use in improving neurological function following ischemic or hemorrhagic stroke[1][3][9]. The specific molecular targets are not well characterized in Western pharmacological terms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naoxuekang.